Suppression of the PI3K/AKT/mTOR signaling pathway by PDYN alleviates sepsis-associated encephalopathy in mice

Ao Li1, Shujuan Qu1, Shengfeng Wang2

  • 1Department of Paediatrics, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, China.

Brain Research Bulletin
|January 16, 2026
PubMed
Abstract

Insights

Prodynorphin (PDYN) protects against sepsis-associated encephalopathy (SAE) by reducing neuroinflammation. PDYN inhibits microglial pyroptosis via the PI3K/AKT/mTOR pathway, offering a new therapeutic target for SAE.

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Microglial pyroptosis drives neuroinflammation in Sepsis-Associated Encephalopathy (SAE).
  • The role of prodynorphin (PDYN) in SAE and its connection to microglial pyroptosis are currently unknown.

Purpose of the Study:

  • To investigate the neuroprotective role of PDYN in SAE.
  • To elucidate the relationship between PDYN and microglial pyroptosis in SAE.

Main Methods:

  • Utilized a mouse model of sepsis (cecal ligation and puncture) and in vitro LPS-treated microglial cells.
  • Assessed cognitive function, glial apoptosis, microglial infiltration, and histopathological changes.
  • Analyzed pyroptosis and signaling molecules via Western blot.

Main Results:

  • PDYN demonstrated neuroprotective effects against neuronal damage and cognitive decline in septic mice.
  • PDYN suppressed microglial pyroptosis and inflammatory cytokine release both in vivo and in vitro.
  • PDYN inhibited microglial pyroptosis by downregulating the PI3K/AKT/mTOR signaling pathway.

Conclusions:

  • PDYN confers neuroprotection in SAE by inhibiting microglial pyroptosis through the PI3K/AKT/mTOR pathway.
  • PDYN and the PI3K/AKT/mTOR-pyroptosis axis represent potential therapeutic targets for SAE.
  • Findings support PDYN as an adjunctive neuroprotective strategy for sepsis care.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
12.1K